Vadadustat
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Vadadustat
- Accession Number
- DB12255
- Description
Vadadustat has been used in trials studying the treatment of Anemia and Non-dialysis-dependent Chronic Kidney Disease.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 306.7
Monoisotopic: 306.0407345 - Chemical Formula
- C14H11ClN2O4
- Synonyms
- Not Available
- External IDs
- Akb 6548
- AKB-6548
- B-506
- B506
- PG-1016548
- PG1016548
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as n-acyl-alpha amino acids. These are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- N-acyl-alpha amino acids
- Alternative Parents
- Phenylpyridines / Pyridinecarboxylic acids and derivatives / 2-heteroaryl carboxamides / Chlorobenzenes / Hydroxypyridines / Aryl chlorides / Vinylogous acids / Heteroaromatic compounds / Secondary carboxylic acid amides / Azacyclic compounds show 7 more
- Substituents
- 2-heteroaryl carboxamide / 3-phenylpyridine / Aromatic heteromonocyclic compound / Aryl chloride / Aryl halide / Azacycle / Benzenoid / Carbonyl group / Carboxamide group / Carboxylic acid show 20 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- I60W9520VV
- CAS number
- 1000025-07-9
- InChI Key
- JGRXMPYUTJLTKT-UHFFFAOYSA-N
- InChI
- InChI=1S/C14H11ClN2O4/c15-10-3-1-2-8(4-10)9-5-11(18)13(16-6-9)14(21)17-7-12(19)20/h1-6,18H,7H2,(H,17,21)(H,19,20)
- IUPAC Name
- 2-{[5-(3-chlorophenyl)-3-hydroxypyridin-2-yl]formamido}acetic acid
- SMILES
- OC(=O)CNC(=O)C1=C(O)C=C(C=N1)C1=CC(Cl)=CC=C1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 23634441
- PubChem Substance
- 347828530
- ChemSpider
- 34958379
- BindingDB
- 107704
- ChEMBL
- CHEMBL3646221
- ZINC
- ZINC000117532869
- PDBe Ligand
- A1Z
- Wikipedia
- Vadadustat
- PDB Entries
- 5opc / 5ox6
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Other Healthy Volunteers 1 3 Completed Treatment Anemia in Subjects With DD-CKD 1 3 Completed Treatment Anemia; Non-dialysis Dependent Chronic Kidney Disease 1 3 Completed Treatment Anemia; Peritoneal Dialysis Dependent Chronic Kidney Disease 1 3 Completed Treatment Anemia / Hemodialysis-dependent chronic kidney disease (HDD-CKD) 1 3 Completed Treatment Anemia / Non-dialysis-dependent Chronic Kidney Disease 2 3 Completed Treatment Iron Deficiency Anemia caused by hemodialysis-dependent chronic kidney disease (HDD-CKD) 2 3 Recruiting Treatment Anemia 1 3 Withdrawn Treatment Anemia / Hemodialysis-dependent chronic kidney disease (HDD-CKD) 1 2 Completed Treatment Anemia / Chronic Kidney Disease (CKD) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0436 mg/mL ALOGPS logP 2.53 ALOGPS logP 2.2 ChemAxon logS -3.8 ALOGPS pKa (Strongest Acidic) 3.12 ChemAxon pKa (Strongest Basic) 1.15 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 3 ChemAxon Polar Surface Area 99.52 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 75.51 m3·mol-1 ChemAxon Polarizability 29.63 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created on October 20, 2016 15:44 / Updated on June 12, 2020 10:53